The generic version of Lumify might become available after 14 July, 2030. This is due to its last patent, 'Preferential vasoconstriction compositions and methods of use', set to expire on that date.
Lumify relieves redness of the eye due to minor eye irritations. Its active ingredient, brimonidine tartrate, is a highly effective agent in relieving these symptoms.
Lumify holds three patents, with the latest one - 'Preferential vasoconstriction compositions and methods of use' - set to expire on 14 July, 2030. Because of this, the Lumify generic might not be available until after this date. Below are the details of the patent: